Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2016Drug Design Development and TherapyOpen Access

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations

View Full Paper
Ask AI
Bookmark
Share

Authors

DKDilek KeskinSSSevil SadriAEAhmet Emre Eşkazan

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Keskin et al. (2016) studied this question.

synapsesocial.com/papers/6a1bf535b33628da419d0b79https://doi.org/10.2147/dddt.s85050
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase2013 · 17 citations
  2. 2The role of dasatinib in the management of chronic myeloid leukemia2015 · 72 citations
  3. 3An epidemiological study of pulmonary arterial hypertension2007 · 799 citations
  4. 4Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia2009 · 208 citations